CannabiNext®

Overview

CannabiNext®, developed by İmuneks Farma, uses internationally patented technology to enhance the solubility and bioavailability of cannabinoids. It is reported to achieve significantly higher blood concentrations than conventional cannabinoid products.

It is formulated with GRAS-status excipients approved by regulatory authorities such as the FDA, EFSA and KFDA.

It offers rapid onset and extended duration of effect; in powder or liquid form, it is suitable for food, beverage, pharmaceutical and nutraceutical applications.

Applications

CannabiNext® delivers high cannabinoid bioavailability in a convenient, flexible format.

It can be used as a powerful standalone ingredient or within innovative combination formulas. It is suitable for once-daily dosing.

In powder or liquid format, it can be incorporated into food, beverage, pharmaceutical and nutraceutical products.

Key features

It is reported to achieve over 500% higher blood concentration compared to conventional cannabinoid products.

Up to 32 times higher blood concentration has been reported compared with standard CBD formulations.

Only GRAS (Generally Recognized As Safe) excipients approved by major regulatory authorities, including the U.S. FDA, EFSA, Japan, KFDA and the Chinese FDA, are used.

It offers rapid onset and extended duration of effect.

It is available in powder or liquid formats.

Mechanism of action

CannabiNext® uses a patented formulation technology developed by İmuneks Farma. This technology significantly increases the water solubility of cannabinoids, thereby enhancing absorption and, consequently, bioavailability.

Higher solubility provides higher blood concentration and faster onset of effect compared to conventional cannabinoid products.